A collaborative research and development program between Microbia, Inc. and DuPont Central Research & Development seeks to develop an economically viable process for a chemical currently manufactured from petrochemicalbased raw material.
From its perspective, DuPont feels that Microbia has the capability to accelerate the rate of process development for the project. John Pierce, director of DuPont's Biochemical Science & Engineering Section of Central Research & Development notes, "We believe Microbia's association analysis technologies will more rapidly identify those genetic elements essential for solving a complex biological challenge, and, when combined with our metabolic engineering capabilities, will accelerate our commercialization timeline."
Richard Bailey, Ph.D., vice president and general manager of Microbia's Precision Engineering business, says, "Not only does this collaboration provide further validation of our technology but it also aligns Microbia with a worldwide leader in the increasingly important area of green chemistry."
Explore the April May 2006 Issue
Check out more from this issue and find your next story to read.
Latest from Today's Medical Developments
- NextDent 300 MultiJet printer delivers a “Coming of Age for Digital Dentistry” at Evolution Dental Solutions
- Get recognized for bringing manufacturing back to North America
- Adaptive Coolant Flow improves energy efficiency
- VOLTAS opens coworking space for medical device manufacturers
- MEMS accelerometer for medical implants, wearables
- The compact, complex capabilities of photochemical etching
- Moticont introduces compact, linear voice coil motor
- Manufacturing technology orders reach record high in December 2025